Patents by Inventor Kung-Cheng Liu

Kung-Cheng Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced anti-influenza agents conjugated with anti-inflammatory activity
    Patent number: 10130714
    Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 20, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng
  • ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY
    Publication number: 20130274229
    Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng